Larosa Joseph J
LAROSA JOSEPH J, GC, reported a transaction classified as withholding at REGENERON PHARMACEUTICALS, INC. involving 8686.000000 shares for an estimated $8256043.00. Reported holdings after the transaction were 43372.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Nov 02, 2026
- Filing date
- Nov 04, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
REGN price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- withholding Code F
- Identifier
- 0001238303-26-000004 Common Stock
- Transaction date
- Nov 02, 2026 Filed Nov 04, 2026, 09:04 PM · 2d delay
- Shares
- 8,686 sh $950.50 per share
- Estimated value
- -$8.25M Computed from shares × price
- Holdings after
- 43,372 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - tax_withholding-22 points
transaction_code = F
Tax withholding on vesting shares is mechanical.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
EVP General Counsel and Secret
- F1
Represents volume-weighted average price of sales of 3,939 shares of Company stock on November 2, 2026 at prices ranging from $965.00 to $965.99. Upon request by the Commission staff, the Company, or…
- F2
Represents volume-weighted average price of sales of 527 shares of Company stock on November 2, 2026 at prices ranging from $966.00 to $966.32. Upon request by the Commission staff, the Company, or a…
- F3
The stock option award vested in four equal annual installments, commencing one year after the date of grant.
0 other transactions
0 recent txs